最近浏览

实时行情

意见反馈

再鼎医药

NASDAQ:ZLAB 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 贝塔系数：
    每股收益：
成交量

董事会

Ying Du
Ying Du is the founder of Hutchison MediPharma Ltd. (2002, Chief Executive Officer), Zai Lab Ltd. (2014, Chairman & Chief Executive Officer), and Zai Venture Partners (2017, General Partner). Dr. Du is currently a Director at Eden Biologics, Inc. (2012 - present). Former positions include Chief Scientific Officer at HUTCHMED (China) Ltd., Executive Vice President-Healthcare Investment at Hutchison Whampoa (China) Ltd., and Venture Partner at Wuhan HongShan Huanxia Technology Co., Ltd. Education includes a doctorate from the University of Cincinnati (Ohio, 1994) and an undergraduate degree from Jilin University (1987).
John D. Diekman
John D. Diekman was the founder of Bay City Capital LLC, founded in 1998, where he was Managing Director from 1998 to 2002. Dr. Diekman is the founder of 5AM Venture Management LLC, founded in 2002, where he is Founding Partner. Dr. Diekman is the founder of Wildcat Discovery Technologies, Inc., founded in 2006, where he is Director. Dr. Diekman currently serves as Director at Cleave Therapeutics, Inc. Dr. Diekman is Independent Director at Zai Lab Ltd. since 2017. Dr. Diekman is Member-Managers Board at Calibrium LLC. Dr. Diekman is Trustee at Princeton University. Former positions include Chairman at The Scripps Research Institute, Chairman & Managing Director at Affymax NV in 1995, Chairman at Ambrx, Inc., Chairman at Envoy Therapeutics, Inc., Chairman at IDEAYA Biosciences, Inc. from 2015 to 2020, Independent Director at Affymetrix, Inc. from 2011 to 2013, and Director at LJL Biosystems, Inc., Ventro Corp., Kalypsys, Inc., Phenomix Corp. from 2002 to 2010, GenoSpectra, Inc., Ingenuity Systems, Inc., Antipodean Pharmaceuticals, Inc., Marcadia Biotech, Inc., Igenica Biotherapeutics, Inc., Bio*One Capital Pte Ltd., S*BIO Pte Ltd., PhaseRx, Inc., Cellular Research, Inc., and Trustee at California Institute of Technology. Education includes a doctorate from Stanford University conferred in 1969, a doctorate from Monash University, and an undergraduate degree from Princeton University conferred in 1965.
Peter Karl Wirth
Peter Karl Wirth was the founder of Lysosomal Therapeutics, Inc. since 2011, holding the title of President & Director from 2011 to 2014. Current jobs include Chairman at Forma Therapeutics, Inc., Director at Centrexion Therapeutics Corp., and Independent Director at Zai Lab Ltd. since 2020. Former jobs include Chairman at Forma Therapeutics Holdings, Inc. from 2012 to 2022, Executive Chairman at ZappRx, Inc. from 2016 to 2018, Chairman at Syros Pharmaceuticals, Inc. from 2017 to 2025, Director at EPIX Pharmaceuticals, Inc., Director at Aura Biosciences, Inc. from 2013 to 2017, Independent Director at Synageva BioPharma Corp. from 2013 to 2015, Secretary, Chief Risk Officer & Executive VP-Legal at Genzyme Corp. from 2009 to 2011, Head-Technology Group & Partner at Palmer & Dodge LLP, and Venture Partner at Quan Capital Management (US) LLC from 2018 to 2023. Education includes an undergraduate degree from the University of Wisconsin conferred in 1972 and a graduate degree from Harvard Law School conferred in 1975.
William David Lis
William David Lis currently works at Jasper Tx Corp., as Executive Chairman & Chief Executive Officer from 2019, Tr1x, Inc., as Executive Chairman from 2025, and Zai Lab Ltd., as Independent Director from 2018. Mr. Lis also formerly worked at Portola Pharmaceuticals LLC, as Chief Executive Officer & Director from 2012 to 2018, Jasper Therapeutics, Inc., as Non-Executive Chairman from 2022 to 2023, COR Therapeutics, Inc., as Product Director from 1999 to 2002, Millennium Pharmaceuticals, Inc., as Marketing Director, Portola Pharmaceuticals LLC, as Senior Director-Business Development in 2005, Biotechnology Innovation Organization, as Director, Eidos Therapeutics, Inc., as Independent Director from 2018 to 2021, Scios, Inc., as Vice President-Business Development from 2007 to 2008, and Ethicon Endo-Surgery, Inc., as Principal. Mr. Lis received his undergraduate degree from the University of Maryland.
Leon Oliver Moulder
Leon Oliver Moulder founded Tellus BioVentures LLC in 2019, where he is working as Managing Member, Tesaro, Inc. in 2010, where he is working as Chief Executive Officer & Director from 2012, and Zenas BioPharma, Inc. in 2019, where he is working as Chairman & Chief Executive Officer from 2023. Mr. Moulder also founded Zenas BioPharma (USA) LLC, where he is working as Chief Executive Officer. Mr. Moulder also currently works at Temple University Japan, as Chairman, Dianthus Therapeutics OpCo, Inc., as Chairman, Helsinn Healthcare SA, as Director from 2020, and various other companies. Mr. Moulder also formerly worked at MGI PHARMA, Inc., as President, Chief Executive Officer & Director from 2003 to 2008, Abraxis BioScience, Inc., as Vice Chairman, President & Chief Executive Officer from 2009 to 2010, MGI PHARMA Biologics, Inc., as President & Chief Executive Officer from 2003 to 2008, and various other companies. Mr. Moulder received his undergraduate degree in 1980 from Temple University (Pennsylvania) and Masters Business Admin degree in 1997 from The University of Chicago Booth School of Business.
Scott William Morrison
Scott William Morrison currently works at Corvus Pharmaceuticals, Inc., as Independent Director from 2015, Zai Lab Ltd., as Independent Director from 2021, IDEAYA Biosciences, Inc., as Independent Director from 2018, Tarsus Pharmaceuticals, Inc., as Independent Director from 2022, and Vera Therapeutics, Inc., as Independent Director from 2020. Mr. Morrison also formerly worked at Biotechnology Innovation Organization, as Director-Emerging Companies Section, Symic Bio, Inc., as Director, The Bay Area Bioscience Association, as Director, The Biotechnology Institute, as Director & Treasurer, Global Blood Therapeutics, Inc., as Independent Director from 2015 to 2022, Astellas Gene Therapies, Inc., as Independent Director from 2015 to 2020, The Life Sciences Foundation, as Director, ESCAPE Bio, Inc., as Independent Director from 2020 to 2022, California Life Sciences Association, as Director, and Ernst & Young LLP, as Partner from 1996 to 2015. Mr. Morrison received his undergraduate degree from Haas School of Business.
Richard Brian Gaynor
Dr. Richard B. Gaynor, MD, is an Independent Director at Zai Lab Ltd., an Independent Director at Alkermes Plc and a President, Head-Research & Development at BioNTech US, Inc. He is on the Board of Directors at Zai Lab Ltd., Alkermes Plc, Alkermes, Inc. and The Damon Runyon Cancer Research Foundation. Dr. Gaynor was previously employed as an Independent Director by Infinity Pharmaceuticals, Inc., a Senior VP-Clinical Development & Medical Affairs by Eli Lilly & Co., a Director-Simmons Cancer Center by The University of Texas Southwestern Medical Center, a Director & Chief-Hematology by Harold C Simmons Comprehensive Cancer Center, and a Senior VP-Clinical Development & Medical Affairs by Lilly Oncology. He received his undergraduate degree from Texas Tech University and a doctorate degree from The University of Texas Southwestern Medical Center.
Wing Yu Leung
Wing Yu Leung is the founder of Biomedic Holdings Ltd., founded in 2004. Current jobs include Director at Pacific Advantage (International) Ltd., Independent Director at Zai Lab Ltd. since 2020, Director at dMed Biopharmaceutical Technology (Shanghai) Co., Ltd. since 2016, Director at Zhejiang Nurotron Nerve Electronic Technology Co Ltd since 2014, Director at New Horizon Health Sciences Co. Ltd. since 2018, Director at Hangzhou New Horizon Health Technology Co., Ltd. since 2017, Director at Nurotron Biotechnology, Inc., Director at Beijing Shenogen Pharma Group Ltd., and Partner at Qiming Development Hk Ltd. since 2007. Former jobs include Vice Chairman at Venus Medtech (Hangzhou), Inc. from 2013 to 2022, Director at Goodwill E-Health Info Co., Ltd., Director at Sangon Biotech (Shanghai) Co., Ltd., Director at Gan & Lee Pharmaceuticals Co., Ltd. from 2010 to 2021, Director at Berry Genomics Co., Ltd. from 2013 to 2017, Director at Fujian Herui Gene Technology Co., Ltd., Non-Executive Director at New Horizon Health Ltd. from 2020 to 2022, Director at Berry Oncology Co. Ltd., Non-Executive Director at CanSino Biologics, Inc. from 2015 to 2024, Independent Non-Executive Director at Hong Kong Exchanges & Clearing Ltd. from 2021 to 2025, Venture Partner at PacRim Venture Partners, Partner at PacRim Venture Partners from 2001 to 2003, Principal at MFVC, Inc., and Managing Partner at Qiming Venture Partners Ltd. from 2009 to 2025. Education includes an MBA from Stanford University and Stanford Graduate School of Business conferred in 2001, and undergraduate degrees from Cornell University in 1992 and the University of Illinois.